Fairvalue-Calculator Fairvalue-Calculator
EN DE

Qian Yuan Baixing, Inc (QYBX) Fair Value & Analysis

Consumer Cyclical · US · Market cap $559K

Price$0.0061
Fair Value$0.0065
Upside+6.1%
Quality95/100
Evidence: High Range $0.0061 – $0.0065

Fair value as of: Jun 26, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Qian Yuan Baixing, Inc (QYBX) currently trades at $0.0061, while our model-based Fair Value estimate is $0.0065 — implying the stock looks roughly 6.1% undervalued today. We read business quality at 95/100 (high quality), in the Consumer Cyclical sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

Qian Yuan Baixing, Inc. focuses on the medical equipment diagnostic and biotech business. The company was formerly known as MDCorp. and changed its name to Qian Yuan Baixing, Inc. in May 2018. Qian Yuan Baixing, Inc. was founded in 2005 and is based in Seattle, Washington.

Open the full interactive analysis →

Similar stocks

Amazon.com, Inc (AMZ) -25% Alibaba Group (BABA) -28% Naspers Limited (NAPRF) -82% PDD Holdings (PDD) +128% Prosus N.V (PROSF) +49% MercadoLibre, Inc (MELI) +15%

Frequently asked questions

Is Qian Yuan Baixing, Inc (QYBX) undervalued?
As of Jun 26, 2026, our model estimates a fair value of $0.0065 versus a price of $0.0061 — about +6% (undervalued). Model-based estimate, not financial advice.
What is the fair value of QYBX?
Our 21-model fair value for Qian Yuan Baixing, Inc is $0.0065 (as of Jun 26, 2026), built from audited fundamentals. The current price is $0.0061.
What is the quality score of QYBX?
Qian Yuan Baixing, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.